Skip to content
Companies

Pacegenix

Prodrugs for atrial fibrillation and fast heart rates

Raised to date

$22.5M

of $22.5M offered across 1 Form D filing

Investors
15
Last filed
Mar 26, 2026

About

Pacegenix is a Cambridge, Massachusetts clinical-stage biotech developing precision cardiology therapeutics for cardiac rhythm disorders. Its pipeline consists of first-in-class prodrugs aimed at rhythm and rate control in patients underserved by existing antiarrhythmic drugs. Lead program PACE-101 targets atrial fibrillation in hypertrophic cardiomyopathy (AF-HCM), where standard antiarrhythmics are contraindicated or ineffective; PACE-201 targets inappropriate rapid heart rates including inappropriate sinus tachycardia and tachycardia in heart failure. The company was founded in 2024, incubated by Genesis BioCapital, and is led by CEO Jay Wohlgemuth, MD.

Prodrug approach designed to control heart rhythm and rate in populations where current antiarrhythmics are contraindicated or compromise cardiac function, with PACE-101 aiming to be the first approved therapy for atrial fibrillation in hypertrophic cardiomyopathy.

Funding

  • EquityFiled Mar 26, 2026Form D
    $22.5M/ $22.5M

Product

PACE-101

Cardiovascular therapeutic (drug candidate)

A rhythm-control drug candidate targeting atrial fibrillation in patients with hypertrophic cardiomyopathy (AF-HCM).

  • Rhythm-control mechanism for atrial fibrillation
  • Targeted at the hypertrophic cardiomyopathy population
  • Prodrug design intended to improve the therapeutic window

Built for

Cardiologists and electrophysiologists treating patients with atrial fibrillation, hypertrophic cardiomyopathy, inappropriate sinus tachycardia, and heart-failure-related arrhythmias

People on file